Gene: RNF181
Official Full Name: ring finger protein 181provided by HGNC
Gene Summary: RNF181 binds the integrin alpha-IIb (ITGA2B; MIM 607759)/beta-3 (ITGB3; MIM 173470) complex and has E3 ubiquitin ligase activity (Brophy et al., 2008 [PubMed 18331836]).[supplied by OMIM, Dec 2008]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO00422 | RNF181 Knockout cell line (HEK293) | Human | RNF181 | 1:3~1:6 | Negative | Online Inquiry |
KO22790 | RNF181 Knockout cell line (HeLa) | Human | RNF181 | 1:3~1:6 | Negative | Online Inquiry |
KO22791 | RNF181 Knockout cell line (HCT 116) | Human | RNF181 | 1:2~1:4 | Negative | Online Inquiry |
KO22792 | RNF181 Knockout cell line (A549) | Human | RNF181 | 1:3~1:4 | Negative | Online Inquiry |
RNF181 Gene Knockout Cell Lines are specialized cell lines in which the RNF181 gene has been selectively disrupted, providing a unique tool for studying the functional implications of this gene in human biology. RNF181 is implicated in various cellular processes, including protein ubiquitination and degradation, which are critical for maintaining cellular homeostasis and mediating responses to environmental stimuli. By creating these knockout models, researchers can investigate the cellular mechanisms underpinning RNF181's role in essential biological pathways, such as immune response regulation and oncogenesis.
The primary mechanism of action involves the deletion of the RNF181 gene, resulting in a loss of function that enables scientists to observe phenotypic changes associated with the absence of this critical protein. This allows for detailed studies into the gene's contribution to disease states, aiding in the identification of novel therapeutic targets. The use of gene knockout technology has revolutionized molecular biology, enabling precise genetic manipulations to elucidate complex biological functions.
Furthermore, RNF181 Gene Knockout Cell Lines hold significant importance in both research and clinical settings. They can be utilized in drug discovery, high-throughput screening, and functional genomics, supplied with detailed tissue-specific contexts that reveal insights unique to the expression of RNF181. This facilitates the development of more effective therapeutic strategies, particularly in cancer and immunological contexts, where dysregulation of ubiquitin-proteasome pathways is often evident.
One of the key advantages of utilizing RNF181 Gene Knockout Cell Lines is the specificity and efficiency they offer compared to conventional knockout methods. These cell lines ensure consistent outcomes due to the standardized genetic background, reducing variability associated with traditional techniques, thus enhancing reproducibility in experimental results.
Given the increasing demand for precise genetic models in biomedical research, the availability of RNF181 Gene Knockout Cell Lines represents a valuable resource not only for academic researchers but also for clinical institutions aiming to translate bench-side findings into therapeutic advancements. Our company, committed to the development of innovative biological products, leverages cutting-edge techniques to ensure our offerings meet the highest scientific and ethical standards, facilitating groundbreaking discoveries in molecular and cellular biology.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.